MDNA 413

Drug Profile

MDNA 413

Alternative Names: MDNA413

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer Medicenna Therapeutics; Stanford University
  • Class Antineoplastics; Cytokines; Interleukins; Recombinant fusion proteins; Small molecules
  • Mechanism of Action Interleukin 4 receptor type II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Atopic dermatitis; Solid tumours

Most Recent Events

  • 16 Mar 2017 Medicenna Therapeutics enter into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to develop fusion protein therapeutics targeting the IL 4 receptor and to advance preclinical development of Empowered Cytokines™ based on IL 4 and IL 13 Superkine™ platform
  • 02 Mar 2017 Medicenna Therapeutics Inc. has been acquired by Medicenna Therapeutics Corp
  • 15 Dec 2016 Preclinical trials in Solid tumours, Atopic dermatitis and Asthma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top